Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Oncolytic Virus Therapy Market size was valued at USD 23.09 million in 2024 and is expected to reach USD 490.46 million by 2037, registering around 26.5% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of oncolytic virus therapy is evaluated at USD 27.99 million.
The reason behind the growth is impelled by the increasing prevalence of cancer globally which has led to a rapid increase in clinical trials and approval of new virus therapies for cancer treatment. Clinical trials are being conducted to determine the effectiveness of oncolytic viruses since they are effective in treating specific cancer types.
Further, oncolytic viruses (OVs) are an emerging class of cancer therapies that use modified viruses to attack and destroy tumor cells and are being used to treat cancer, particularly advanced metastatic melanoma. According to the World Health Organization (WHO), cancer is a leading cause of death worldwide, accounting for about 10 million death in 2020.
The growing advancements in viral engineering are believed to fuel the market growth. The viral-vector production has had to quickly advance therefore, numerous technological innovations are being tested by businesses to handle every aspect of viral-vector gene therapy, and as genetic engineering technology has advanced, capabilities of the oncolytic virus have been enhanced for creating new anticancer techniques, and the development of tumor-selective oncolytic virus with effectiveness against a variety of malignancies has been made possible.
Oncolytic Virus Therapy Sector: Growth Drivers and Challenges
Growth Drivers
- Rising Demand for Personalized Treatment– Multiple scientific advancements and a growing number of different pharmaceutical businesses have contributed to the rise of personalized medicine. With personalized treatment, oncologists can customize the oncolytic viruses to target specific genetic alterations to increase the chances of therapeutic success.
Over 38% of all new pharmaceuticals approved by the US Food and Drug Administration (FDA) in 2020 were personalized medicine therapy. - Increasing Geriatric Population – The elderly population is more susceptible to cancer, and as people age their cellular repair mechanism gets less effective, which is expected to drive the demand for oncolytic virus therapy since aged people with cancer look for better treatment options.
The global population of those 65 and older is increasing more rapidly, and lately, there are over 610 million persons over the age of 65.
Challenges
- Side Effects of the Therapy– Oncolytic viruses occasionally may contaminate healthy cells and excite overall immune movement, and they may also transmit a potential risk of infection. The common side effects are chills, fatigue, flu-like indications, injection site pain, sickness, and fever which negatively affect the market growth.
- Limited Access to Healthcare in Low and Middle Income Countries
- Lack of Professionals to Perform the Therapy- since Intratumoral injections are difficult to perform, ordinary nurses cannot administer these injections.
Oncolytic Virus Therapy Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
26.5% |
|
Base Year Market Size (2024) |
USD 23.09 million |
|
Forecast Year Market Size (2037) |
USD 490.46 million |
|
Regional Scope |
|
Oncolytic Virus Therapy Segmentation
Therapy Type (HSV-based, Adenovirus-based, Reovirus, Poxviruses, NDV)
The HSV-based oncolytic virus therapy market is estimated to gain a robust revenue share of about 30% in the coming years owing to the large number of clinical trials ongoing related to HSV-based viruses. For instance, HSV has two existing variants: HSV Type 1 (HSV-1) and HSV Type 2 (HSV-2). Among these two existing variants HSV-1 has been widely investigated in cancer oncolytic viral therapy. Approximately, 58% of the U.S. population and around 67% of the global population have evidence of exposure to HSV-1 at the same point during their lifetime. Furthermore, genomic manipulation, cytotoxicity, pathogenicity, and the availability of antiviral drugs have resulted in the growing demand for oncolytic HSV-1 widely as a therapeutic approach to melanoma.
End-User (Hospitals, Specialty Clinics, Cancer Research Institutes)
The hospitals segment in the oncolytic virus therapy market is set to garner a notable share in near future as most of the patients approach these facilities for the treatment. Patients with diseases such as cancer, when receiving an early diagnosis in hospitals, their survival rate and chances for successful treatment increase significantly. Within the hospital premises round the clock healthcare professionals including medical oncologists, and other specialists are available to help patients with cancer in the treatment planning.
Our in-depth analysis of the global market includes the following segments:
|
Therapy Type |
|
|
Virus Type |
|
|
Indication |
|
|
Demography |
|
|
End-User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportOncolytic Virus Therapy Industry- Regional Synopsis
North American Market Forecast
Oncolytic virus therapy market in North America is predicted to account for the largest share of about 39% by the end of 2037 impelled by the growing clinical activities. This has led to the development of new oncolytic viruses’ modifications to existing viruses in the region for serious diseases including cancer. As a result, the demand for oncolytic virus therapy may increase in the region as new modifications would offer more benefits and more patients become eligible for the treatment.
In terms of the number of clinical trial sites, followed by the United States Canada accounts for more than 3% of all global clinical trials.
European Market Statistics
The Europe oncolytic virus therapy market is estimated to be the second largest, during the forecast timeframe led by the rising approvals of oncolytic virus therapy drugs. This has led to the development of new oncolytic viruses’ modifications to existing viruses in the region for serious diseases including cancer. As a result, the demand for oncolytic virus therapy may increase in the region as new modifications would offer more benefits and more patients become eligible for the treatment.
Companies Dominating the Oncolytic Virus Therapy Landscape
- Amgen Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Shanghai Sunway Biotech Co. Ltd.
- Oncolys BioPharma Inc.
- TILT Biotherapeutics Ltd.
- Oncorus Inc
- TAKARA BIO INC.
- Vyriad
- Transgene SA
- Lokon Pharma AB
- Pfizer Inc.
- Rigvir Group
- Sibiono GeneTech Co. Ltd.
- Oncolytics Biotech
- Daiichi Sankyo
- Kissei Pharmaceutical Co., Ltd.
- Boehringer Ingelheim
In the News
- Daiichi Sankyo announced that it has received approval for its oncolytic virus G47 (trade name: DELYTACT). The approval is primarily based on the Japan Ph2 research (investigator led-study) findings led by Dr. Todo of the Institute of Medical Science, The University of Tokyo undertaken in patients with residual or recurrent glioblastoma.
- TILT Biotherapeutics Ltd. partnered with Biotheus Inc. to promote the global development and marketing of TILT-123, a cancer treatment product, and also make it available to Chinese cancer patients. Further, the agreement involves a down payment as well as payments at specified points in the clinical research process and is qualified to collect large royalties on future sales payments.
Author Credits: Radhika Pawar
- Report ID: 2988
- Published Date: Nov 08, 2024
- Report Format: PDF, PPT
